See Why Jefferies Sees Massive Upside In Global Blood Therapeutics

Jefferies initiated coverage of Global Blood Therapeutics Inc GBT with a Buy rating and $68 price target. The analyst sees an upside of almost 145%.
Oxbryta's implied sickle cell disease (SCD) market share is only 5%-6% at the stock's current valuation.
Still, analyst Akash Tewari sees a 22% share and models $1.1 billion in peak sales for the drug in that indication.
Related: Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use.
Meanwhile, Tewari calls GBT601 "the most promising preclinical candidate in development for SCD" and sees both valuation and timing making the stock "a top pick heading into ASH," the analyst said.
Related: Global Blood Shoots 17% Higher As Q2 Earnings Beat Estimates; Analyst Upgrades Stock.
Price Action: GBT stock is up 9.96% at $27.94 during the market session on the last check Thursday.